#long-acting injectables

ViiV Cabenuva injectable cabotegravir rilpivirine

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

Thigh Injections Might Be an Option for Cabenuva and Apretude

Some people found thigh injections less painful than butt shots, and this could potentially enable self-administration at home.

Black Gay Men and Trans Women Are Well Protected by Injectable PrEP

Black gay men and transgender women were more likely to maintain good adherence with every-other-month shots versus daily pills.

CDC’s Dr. Mermin and Dr. Brooks Share Mpox and HIV Prevention Highlights from CROI 2023 [VIDEO]

Conference highlights included studies on mpox, HIV PrEP, STI post-exposure prophylaxis and long-acting HIV treatment.

Dr. Dieffenbach Shares Research Highlights From CROI 2023 [VIDEO]

NIAID director discusses long-acting HIV prevention and treatment, COVID and a cure update.

Sunlenca Plus Two Antibodies Shows Promise for Twice-Yearly Treatment

90% of people who received an injection of lenacapavir plus two broadly neutralizing antibodies maintained viral suppression for six months.

Are Long-Acting Injectables Feasible for People Without Viral Suppression?

People at a safety-net HIV clinic who struggle with adherence had viral suppression rates comparable to those seen in clinical trials.

Prioritizing Equity and Extending Reach

Ensuring underserved populations have access to long-acting injectable HIV treatment.

Ward 86, the First U.S. HIV Clinic, Celebrates 40 Years

The clinic has pioneered innovations that have been adopted nationwide and around the world.

Medicare Seeks Public Input on Covering PrEP to Prevent HIV

Daily pills and long-acting PrEP both scored a grade A for preventing HIV. Now Medicare is considering national coverage.

Twice-Yearly Sunlenca Works Well for Initial HIV Treatment

The new injectable antiretroviral keeps HIV under control, but it still needs an equally long-acting partner.

2022 Top HIV Science Stories

This year’s most widely viewed science news focused on HIV cure research, monkeypox and PEP for sexually transmitted infections.

Sunlenca

Long-Acting Injectable PrEP as HIV Prevention Scores an A Grade

An expert panel’s draft recommendation gives injectable PrEP an A grade, which will make the HIV prevention option more widely available.

Treatment: Self-Administration of Long-Acting Injectables

People could potentially administer Cabenuva for HIV treatment or Apretude for pre-exposure prophylaxis (PrEP) at home.

Progress on Long-Acting HIV Treatment

Long-acting antiretrovirals are the future of HIV treatment, and new meds on the horizon could improve convenience and adherence.

Lenacapavir Shows Continued Promise for People With Drug-Resistant HIV

The long-acting HIV capsid inhibitor worked well for harder-to-treat groups, such as those with a low CD4 count.

#long-acting injectables

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

Gilead and Merck to Collaborate on Next-Generation Long-Acting Rx

Up-and-Coming Long-Acting Treatment

Thigh Injections Might Be an Option for Cabenuva and Apretude

Black Gay Men and Trans Women Are Well Protected by Injectable PrEP

CDC’s Dr. Mermin and Dr. Brooks Share Mpox and HIV Prevention Highlights from CROI 2023 [VIDEO]

Dr. Dieffenbach Shares Research Highlights From CROI 2023 [VIDEO]

Sunlenca Plus Two Antibodies Shows Promise for Twice-Yearly Treatment

Are Long-Acting Injectables Feasible for People Without Viral Suppression?

Prioritizing Equity and Extending Reach

Ward 86, the First U.S. HIV Clinic, Celebrates 40 Years

Medicare Seeks Public Input on Covering PrEP to Prevent HIV

Twice-Yearly Sunlenca Works Well for Initial HIV Treatment

2022 Top HIV Science Stories

Sunlenca

Long-Acting Injectable PrEP as HIV Prevention Scores an A Grade

Treatment: Self-Administration of Long-Acting Injectables

Progress on Long-Acting HIV Treatment

Lenacapavir Shows Continued Promise for People With Drug-Resistant HIV

Science News

Ask POZ